BIIB Biogen Inc.

232.92
+2.16  (+1%)
Previous Close 230.76
Open 230.07
Price To Book 3.27
Market Cap 45161650029
Shares 193,893,397
Volume 1,530,868
Short Ratio
Av. Daily Volume 2,881,518

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2020.
BIIB054
Parkinson's disease
Phase 2 data due 1H 2020.
Natalizumab - OPUS
Epilepsy
Phase 3 commencement of enrollment announced September 4, 2018.
BIIB093
Large hemispheric infarction
Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
CIRARA (intravenous glyburide)
Ischemic stroke
Phase 2 data due 2H 2019.
BIIB092 - Anti Tau
Progressive supranuclear palsy (PSP)
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - EMERGE
Alzheimer’s disease
Phase 3 trial to be initiated later in 2019.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b data due mid-2020.
Opicinumab (AFFINITY)
Multiple sclerosis (MS)
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b data released February 8, 2018 - primary endpoint not met.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 data released September 2018 - primary endpoint not met.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Erythromelagia
Phase 2 data due by end of 2019.
BIIB059 (anti-BDCA2)
Lupus
Phase 2b data released October 23, 2018 - primary endpoint not met.
Dapirolizumab pegol (anti-CD40L)
Lupus
Phase 3 initiation announced March 22. 2019.
BAN2401
Alzheimer’s disease
Phase 2b trial initiated September 2018.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 1/2 data released June 8, 2017.
XLRS Gene Therapy
X-linked retinoschisis (XLRS)
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 data due 2H 2020.
IONIS-SOD1Rx / BIIB067
Amyotrophic lateral sclerosis (ALS)
Phase 3b trial initiation announced January 3, 2019.
Natalizumab - NOVA
Multiple sclerosis (MS)
Phase 2b data due late-2020.
BIIB104
Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase 2 data due late-2020.
TMS-007
Stroke
Phase 2 data due late-2020.
BIIB074 (Nav1.7 inhibitor)
Small Fibre Neuropathy

Latest News

  1. The Best and Worst Big Biotech Stocks, According to One Analyst
  2. We don't yet have the technology to cure Alzheimer's, health-care investor says
  3. Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending
  4. Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer
  5. Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital
  6. Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
  7. Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
  8. Wayfair cracks Fortune 500 list, joins 15 other Mass. companies
  9. Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks
  10. Stocks making the biggest moves premarket: Alibaba, Zillow Group, Biogen, McDonald's, Beyond Meat & more
  11. The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi
  12. 5 Low Price-to-Book Value Stocks for Great Returns
  13. NHS England, Biogen reach deal on pricey drug for deadly disorder
  14. Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
  15. Ionis Pharmaceuticals Is 40% of the Way There
  16. Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
  17. Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease
  18. PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y